Stock-taking conference on the implementation of REACH authorisation

Conference Programme

13-14 November 2017
Marie Curie Conference Centre (ECHA, Helsinki)

All sessions, apart from the world café session, are web-streamed live via WebEx.
Attendees (incl. remote ones) can participate also using the audience interaction platform Slido (www.sli.do, code "#Authorisation2017").
Press will participate. Only confirmed speakers are mentioned in the programme.

Purpose

The purpose of the conference is to take stock of the evolution and achievements of the authorisation process in terms of the progression of substitution, proper control of risks and cost-effectiveness. Furthermore, it will provide a forum for all involved to discuss points for improvement in the application process. The conference will help to further increase confidence and understanding of the application for authorisation process in the future.

Day 1

Registration and coffee (12.00 – 13.00)

Welcome (13.00 – 13.15)

Moderator: Matti Vainio, *ECHA*

- Geert Dancet, *ECHA*
- Christina de Avila, *the European Commission*

Results of the study on the impacts of authorisation (13.15-13.30)

- Valentina Bertato, *the European Commission*

Theme 1 - How the authorisation process has contributed to risk reduction, substitution of SVHCs and what the costs have been

Experiences of the applicants (13.30-16.00)

Moderators: Thierry Nicot, *ECHA,* and Hugo Waeterschoot, *Eurometaux*

- Overview of applicants' experiences, Erwin Annys, *Cefic*
- Experiences of upstream chromates applications, Matthias Enseling, *Hartchrom GmbH*
    - Commentary, Richard Luit, *the Dutch competent authority*
- Experiences of a downstream joint applicant, Rene van Rij, *Hoogovens*
    - Commentary, Simon Cogen, *SEAC*
- We can do it alone – The application process of a small enterprise, Uwe Moeller, *empBiotech*
    - Commentary, Lina Dunauskienė, *RAC*
- Discussion

Coffee break (16.00-16.30)

How the authorisation process has reduced risks (16.30 – 18.25)

Moderators: Markus Berges, *ECHA*, and Bill Frazee, *Huntsman Performance Products*

- How has the authorisation process reduced risks: Results of the European Commission's study on the impacts of authorisation, Hiram Moerman, *Apeiron*
- An SME applicant's experience of risk reduction, Iann Rancé, *Expanscience*
- Authorisation and Risk Reduction - A Member State Perspective, Mark Schwägler, *Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety, Germany*
- Experiences of enforcement, Dimitri De Coninck, *the Belgian competent authority*
- Reduction of risks as a result of the authorisation requirement and the opinion-development, Tim Bowmer, *Chairman of ECHA's Risk Assessment Committee*
    - Commentary, Dolores Romano, *European Environmental Bureau*
- Discussion

Drinks and world café (18.30 – 19.30)

Explained by: Sanna Henrichson, *ECHA*

Short interactive discussions on different aspects of the authorisation process facilitated by various different stakeholders. Participants will move between the different discussion groups every 20 minutes with an aim to contribute with their own experiences and suggestions. The following topics have been identified – but will be adapted based on suggestions made by participants:

- Study on the impacts of authorisation, Rohit Mistry, *eftec*, and Hiram Moerman, *Apeiron*
- REACH beyond 2018 – with special consideration of the regulatory alternatives 'restriction' and 'authorisation, Olaf Wirth, *Ökopol GmbH*
- ECHA's Information bazar on DU notifications
- REACH Clinic (Authorised): whatever you always wanted to know about… come and ask

Dinner at ECHA (19.30 –)

Day 2

Experiences of substitution (8.30 – 10.15)

Moderators: Tomas Öberg, *Chairman of ECHA's Socio-economic Analysis Committee*, and Frida Hök, *ChemSec*

- How has authorisation affected substitution: Results of the European Commission's study on the impacts of authorisation, Rohit Mistry, *eftec*
- Substitution of diarsenic trioxide in Murano glass, Maria Letizia Polci, *the Italian competent authority*
- Experiences of substitution for flame retardants, Erwin Boënne, *CTF 2000*
- Experience of an alternative provider, Rüdiger Schäfer, *Oerlikon*
- Discussion

Coffee break (10.15 – 10.45)

What has the system cost and what are the benefits (10.45-12.15)

Moderators: Christoph Rheinberger, *ECHA,* and Stavros Georgiou, *SEAC*

- What are the costs and the benefits of authorisation: Results of the European Commission's study on the impacts of authorisation, Rohit Mistry, *eftec*
  - Commentary, Hugo Waeterschoot, *Eurometaux*
  - Commentary, Frida Hök, *ChemSec*
- Socio-economic impacts of REACH authorisations — A meta-analysis of the first 100 applications for authorisation, Christoph Rheinberger, *ECHA*
- Discussion

Lunch (12.15-13.15)

Theme 2 – Outlook of the years to come (13.15-15.10)

Moderators: Matti Vainio, *ECHA*, and Anna Borràs, *the European Commission*

Panellists: France Capon, *European Precious Metals Federation*, Richard Luit, *SEAC*, Finn Pedersen, *Danish competent authority*, Dolores Romano, *European Environmental Bureau*, and Martina Vosteen, *Ramboll Environ*

Interactive discussion with the following possible questions:

- How could the authorisation system further stimulate SVHC substitution?
- How to enhance the quantity, quality and usability of information on alternatives submitted by third parties during the public consultation?
- How to improve the risk reduction capacity of the system?
- How to further improve the system for applications, particularly for upstream actors in the supply chain?
- How to improve the efficiency and/or reduce costs of the system?
- How to further improve the formats and key guiding material[1]?
- How to improve the predictability of the system?

Coffee break (15.10-15.40)

Conclusion (15.40-16.00)

- Jack de Bruijn, *ECHA*, and Michael Flueh, *the European Commission*

[1] For instance, application format, opinion format, practical guide, use description guide, checklists, opinion trees, review period, economic feasibility, dose-response curves and DNELs, PSIS material, trialogue.